A Digital Assay to Streamline PD-L1 IHC: Published in Scientific Reports
Jun 14, 2022 Flagship Biosciences, Inc., today announced the publication of a paper describing validation of a novel digital spatial biology assay in Scientific Reports. The assay, Tissue Insight (TI) 22C3 NSCLC, surpasses manual scoring in PD-L1 positive tumor samples. Modern cancer immunotherapy for non-small cell lung cancer (NSCLC) utilizes programmed death-ligand 1 (PD-L1) checkpoint […]
DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus
Jun 09, 2022 DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity’s test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE […]
DxTerity Diagnostics Begins Enrollment in the ELEVATE Clinical Study for Lupus
May 27, 2022 LOS ANGELES, May 27, 2022 /PRNewswire/ — DxTerity Diagnostics today announced the opening of enrollment in ELEVATE (Empower Lupus Erythematous Patients Via Allowing RemoTe Evaluation), a new observational clinical study for patients with Systemic Lupus Erythematosus (SLE or lupus). The study opening aligns with Lupus Awareness Month (May) and efforts to advance precision medicine and improve the lives of patients […]
Foresight Diagnostics Expands Scientific Advisory Board with Appointment of Christopher R. Flowers, M.D., M.S.
Apr 27, 2022 Foresight Diagnostics today announced the appointment of Christopher R. Flowers, M.D., M.S., to its Scientific Advisory Board (SAB). Dr. Flowers is an oncologist specializing in the treatment of B cell lymphoma and rare subtypes of lymphoma. He currently serves as Chair and Professor in the Department of Lymphoma-Myeloma in the Division of Cancer […]